0000891839-20-000030.txt : 20200115 0000891839-20-000030.hdr.sgml : 20200115 20200115162055 ACCESSION NUMBER: 0000891839-20-000030 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20200115 DATE AS OF CHANGE: 20200115 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Van Strydonck, Gerald E. CENTRAL INDEX KEY: 0001748247 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38624 FILM NUMBER: 20528479 MAIL ADDRESS: STREET 1: 1895 MOUNT HOPE AVENUE CITY: ROCHESTER STATE: NY ZIP: 14620 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VACCINEX, INC. CENTRAL INDEX KEY: 0001205922 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 161603202 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 BUSINESS PHONE: 585-271-2700 MAIL ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 FORMER COMPANY: FORMER CONFORMED NAME: VACCINEX INC DATE OF NAME CHANGE: 20021114 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2019-06-30 0001205922 VACCINEX, INC. VCNX 0001748247 Van Strydonck, Gerald E. C/O VACCINEX, INC. 1895 MOUNT HOPE AVENUE ROCHESTER NY 14620 1 0 0 0 Stock Option (Right to Buy) 10.00 2020-03-06 Common Stock 4500 4500 D Stock Option (Right to Buy) 14.90 2023-03-06 Common Stock 7500 7500 D Stock Option (Right to Buy) 13.60 2027-09-15 Common Stock 6396 6396 D Stock Option (Right to Buy) 5.26 2029-03-30 Common Stock 2501 2501 D Stock Option (Right to Buy) 7.78 2020-05-15 Common Stock 7718 7718 D Stock Option (Right to Buy) 5.52 2019-06-30 4 A 0 2385 0 A 2019-06-30 2029-06-29 Common Stock 2385 2385 D Exercisable in full as of the date of this report. This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the second quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. /s/ Scott E. Royer, Attorney-in-Fact for Gerald E. Van Strydonck 2020-01-15